An open pilot study of citalopram for behavioral disturbances of dementia: Plasma levels and real-time observations

American Journal of Geriatric Psychiatry

Volumn 5, Issue 1, 1997, Pages 70-78

  Pollock, Bruce G ^a   Mulsant, Benoit H ^a   Sweet, Robert ^a   Burgio, Louis D ^a   Kirshner, Margaret A ^a   Shuster, Kimberly ^a   Rosen, Jules ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM;

AGED; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; DEMENTIA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; TREATMENT OUTCOME;

EID: 0031036513     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199705010-00009     Document Type: Article

References (34)

1. Deutsch LH, Bylsma FW, Rovner BW, et al: Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 1991; 148:1159-1163
2. Teri L, Rabins P, Whitehouse P, et al: Management of behavior disturbance in Alzheimer's disease: current knowledge and future directions. Alzheimer Dis Assoc Disord 1992; 6:77-88
3. Steele C, Rovner B, Chase GA, et ai: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147:1049-1051
4. Schneider LS, Sobin PB: Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementias. Psychopharmacol Bull 1992; 28:71-79
5. Salzman C:Treatment of agitation in the elderly, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven, 1987, pp 1167-1176
6. Schneider LS, Pollock VE, Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563
7. Devanand DP, Levy SR: Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8(suppl 1): S18-27
8. McKeith I, Fairbairn A, Perry R, et al: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673-678
9. Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402-2406
10. Burke WJ, Folks DG, Roccaforte WH, et al: Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. American Journal of Geriatric Psychiatry 1994; 2:352-354
11. Houlihan DJ, Mulsant BH, Sweet RA, et al: A naturalistic study of trazodone in treatment of behavioral complications of dementia. American Journal of Geriatric Psychiatry 1994; 2:78-85
12. Hyttel J: Pharmacological characterization of selective serotonin inhibitors. Int Clin Psychopharmacol 1994; 9(suppl 1):19-26
13. Nyth A-L, Gottfries C-G: The clinical efficacy of citalopram in treatment of emotional disturbances of dementia disorders. Br J Psychiatry 1990; 157:894-901
14. Burgio LD, Scilley K, Hardin M, et al: Studying disruptive vocalization and contextual factors in the nursing home using computer-assisted realtime observation. J Gerontol 1994; 49:230-239
15. Zubenko GS, Rosen J, Sweet RA, et al: Impact of psychiatric hospitalization on behavioral complications of Alzheimer's disease. Am J Psychiatry 1992; 149:1484-1491
16. Levin HS, High WM, Goethe KE, et al: The neurobehavioral rating scale. J Neurol Neurosurg Psychiatry 1987; 50:183-193
17. Sultzer DL, Levin HS, Mahler M, et al: Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: The Neurobehavioral Rating Scale. J Am Geriatr Soc 1992; 40:549-555
18. Pollock BG, Mulsant BH, Sweet RA, et al: Prospective P450 2d6 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31:327-331
19. Mulsant BH, Pollock BG, Sweet RA, et al: Measuring treatment response in demented patients with behavioral disturbances. J Neuropsychiatry Clin Neurosci 1995; 7:411
20. 20.National Institute of Mental Health: 028 CGI. Clinical Global Impressions, in ECDEU Assessment for Psychopharmacology, Revised Edition. Edited by Guy W. Rockville, MD, 1976, pp 217-222
21. Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU side effect rating scale. Acta Psychiatr Scan 1987; 334(suppl):1-100
22. Øyehaug E, Østensen ET: High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 1984; 308:199-208
23. Burgio LD, Hawkins A: Behavioral assessment of the effects of psychotropic medications on demented nursing home residents. Behav Modif 1991; 15:194-212
24. Burgio LD, Reynolds CF, Janosky JE, et al: A behavioral microanalysis of the effects of haloperidol and oxazepam in demented psychogeriatric patients. Int J Geriatr Psychiatry 1992; 7:253-262
25. Pollock BG, Mulsant BH: Antipsychotics in older patients: a safety perspective. Drugs Aging 1995; 6:312-323
26. Allard PO, Rinne J, Marcusson JO: Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res 1994; 637:262-266
27. Bierer LM, Knott PJ, SchmeidlerJM, et al: Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms. Psychiatry Res 1993; 49:211-217
28. Palmer AM, DeKpsky ST: Neurochemistry of aging, in Clinical Neurology of Aging. Edited by Albert M, Knoefel J. New York, Oxford University Press, 1994, pp 79-101
29. Parnetti L, Gottfries J, Karlsson I, et al: Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of the Alzheimer type using high-performance liquid chromatography and gas chromatographymass spectrometry. Acta Psychiatr Scand 1987; 75:542-548
30. Palmer AM, Francis PT, Benton JS, et al: Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987; 48:8-15
31. Zubenko GS: Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 1992; 6:77-93
32. Richelson E: The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994; 55:(suppl A):34-39
33. Overø KF: Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6:311-318
34. Abernathy DR, Greenblatt DJ, Shader RI: Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985; 232:183-188